Across TCGA pan-cancer cohorts, BRI3BP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BRI3BP data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher BRI3BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BRI3BP expression acts as an unfavorable survival marker.
STAD, LUSC, and KIRP are the cancer types where BRI3BP Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.